Search the Newsreel

Viridian Therapeutics earnings missed by $0.02, revenue topped estimates

Press Release: Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics has released its second quarter 2026 financial results, alongside an update on recent business developments. This announcement provides insights into the company's financial performance and strategic progress during the quarter.

Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending

OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project in Labrador. The initial assay submission includes the …

Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $284,000

Viridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval

Viridian Therapeutics reported a Q2 2026 net loss of $127.1 million, with $981.5 million in cash, cash equivalents, and marketable securities. This report follows the FDA approval and U.S. commercial launch of Lumvoa for thyroid eye disease on June 26, 2026, and the company …

Viridian Therapeutics (VRDN) Earnings Date and Reports 2026

NVRI (NVRI) insider schedules sale of 127 common shares after prior sales

Francis Nicholas Grasberger, an insider at Enviri Corp (NVRI), has filed an intent to sell 127 shares of common stock through UBS Financial Services Inc. This proposed sale follows a previous transaction on July 29, 2026, where Grasberger sold 52,302 shares, generating gross proceeds …

Enviri (NVRI) Projected to Announce Quarterly Earnings on Tuesday

First Trust Advisors LP Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN

First Trust Advisors LP significantly increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 151.5% in the first quarter, now holding 301,529 shares valued at $5.9 million. The clinical-stage biopharmaceutical company, which develops antibody therapies for rare diseases like thyroid eye disease, reported a first-quarter …

(VRDN) Volatility Zones as Tactical Triggers

This article provides an AI-driven analysis of Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting neutral readings in shorter time horizons and a weak bias in the long term. It identifies an exceptional short setup with a significant risk-reward ratio and outlines three distinct trading strategies: …

How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors

Viridian Therapeutics reported positive topline results from its Elegrobart REVEAL-1 phase III trial for Graves' ophthalmopathy, planning a Biologics License Application in early 2027. This, alongside the recent LUMVOA approval, strengthens the company's position in the autoimmune eye disease market, despite continued unprofitability and …

Enviri Corp (NVRI) Financial Health: Profitability & Balance Sheet Analysis

Enviri Corp (NVRI) has a weak financial status with a current score of 6.14, ranking 135 out of 159 in its industry. The company's latest quarterly revenue decreased by 40.90% year-over-year, and its net profit saw a significant decrease of 270.94%. Operational efficiency is …

NVRI|Enviri Corp|Price:22.240|Chg%:+0.050

This article provides a detailed financial overview of Enviri Corp (NVRI), including its stock performance, earnings dates, and analyst ratings. It presents comprehensive quarterly and annual financial statements, such as income statements, balance sheets, and cash flow statements, highlighting key financial indicators like EPS, …

Enviri Corp (NVRI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Enviri Corp (NVRI), highlighting its current valuation score of 8.49 within the Professional & Commercial Services industry. It notes that the company's current P/E ratio is -10.59, which is significantly below its recent high. The article also …

Harsco Environmental earns 4 stars in three workplace awards

Harsco Environmental, a division of Enviri (NYSE: NVRI), has been recognized with three 4-star ratings in Newsweek's 2026 America's Greatest Workplaces awards, including "America's Greatest Workplaces," "America's Greatest Workplaces in Professional Services," and "America's Greatest Workplaces for Culture, Belonging & Community." These awards highlight …

Harsco Environmental Recognized in Three Newsweek America’s Greatest Workplaces Awards

Harsco Environmental, a division of Enviri Corporation, has been recognized in three of Newsweek's America's Greatest Workplaces Awards for 2026, earning a 4-star rating in each category. These include America's Greatest Workplaces, America's Greatest Workplaces in Professional Services, and America's Greatest Workplaces for Culture, …

Enviri Corp (NVRI) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Enviri Corp (NVRI), which has a risk score of 5.07, ranking 92 out of 159 in its industry. The company's beta is 1.61, indicating higher volatility compared to the S&P 500. The assessment details various metrics including …

Enviri Corp (NVRI) Institutional Confidence

Enviri Corp (NVRI) has an institutional shareholding score of 10.00, ranking 1st in its industry. The institutional shareholding proportion has increased by 9.74% quarter-over-quarter, now standing at 121.24%. ETHSX is the largest institutional shareholder with 457.13K shares, representing 0.56% of shares outstanding.

Enviri Corp SEC Filing (Jul 29, 2026)

Enviri Corp (NVRI) filed a Form 144 with the SEC on July 29, 2026, indicating a proposed sale of 52,302 shares of common stock with an aggregate market value of $1,176,795. The securities, acquired through a stock appreciation release from the issuer on the …

Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight

The Graves' ophthalmopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of autoimmune thyroid disorders, improved disease awareness, and earlier diagnosis. Additionally, the recent approval of LUMVOA has heightened competition in the Graves' ophthalmopathy market. Furthermore, …

Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Wednesday

Price to earnings forward of Viridian Therapeutics, Inc. – LSE:0K1R

This article provides the "Price to earnings forward" value for Viridian Therapeutics, Inc. (LSE:0K1R). The core data presented is a single numerical value for this financial metric, alongside its change and percentage change. The article focuses solely on this specific financial data point for …

Enviri Corp (NVRI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Enviri Corp (NVRI), listing its major shareholders and institutional holdings. It identifies top institutional investors such as BlackRock Institutional Trust Company, N.A., and Neuberger Berman, LLC, along with a breakdown of shareholder types. The report also provides …

Viridian Therapeutics Inc (VRDN) Institutional Confidence

Viridian Therapeutics Inc (VRDN) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 8.27% quarter-over-quarter, reaching 112.73%. Steven Cohen is the largest institutional shareholder, holding 365.59K shares and increasing …

Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides an incomplete revenue breakdown for Viridian Therapeutics Inc (VRDN), stating that much of the relevant data has not yet been disclosed by the company. It does, however, show a regional revenue figure for the United States at $70.85 million with a …

Enviri Corp (NVRI) Income Statement

This article provides a detailed quarterly and annual income statement for Enviri Corp (NVRI), including key financial metrics like total revenue, cost of revenue, operating expenses, and net income, dating back to FY2012Q1. It also includes an FAQ section to help users understand how …

Viridian Therapeutics Inc (VRDN) Income Statement

This article provides a detailed quarterly and annual income statement for Viridian Therapeutics Inc (VRDN), covering various financial metrics from total revenue to basic and diluted earnings per share. It also includes frequently asked questions about how to interpret these statements and key metrics …

VRDN|Viridian Therapeutics Inc|Price:19.270|Chg%:+0.010

This article provides a comprehensive stock analysis of Viridian Therapeutics Inc (VRDN) by TradingKey. It highlights the company's strong fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership, a "Buy" rating from …

NVRI|Enviri Corp|Price:22.070|Chg%:-0.350

Enviri Corp (NVRI) is trading at $22.080, down 2.00%. The company has a market cap of $620.53 million, and its fundamentals are considered stable with significant growth potential and a fair valuation. Analysts have rated NVRI as a "Buy" with a target price of …

NVRI|Enviri Corp|Price:22.080|Chg%:-0.450

Enviri Corp (NVRI) is trading at $22.080, down 2.00%. The company has a market cap of $620.53 million, and its fundamentals are considered stable with significant growth potential and a fair valuation. Analysts have rated NVRI as a "Buy" with a target price of …

Viridian Therapeutics stock trades around recent lows as cash runway and thyroid eye trial data shap

Viridian Therapeutics (VRDN) stock is trading around recent lows, influenced by its cash runway and upcoming thyroid eye disease trial data. The biotech company is advancing its lead investigational product for thyroid eye disease, having reported positive mid-stage clinical trial data, but faces challenges …

Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Viridian Therapeutics Inc (VRDN), highlighting its current valuation score of 6.83, which ranks it 295 out of 386 in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -4.82 and mentions that relevant …

Enviri Corp SEC Filing (Jul 21, 2026)

This article details Enviri Corp's (NVRI) Form 144 SEC filing from July 21, 2026, which indicates a proposed sale of 33,940 shares of common stock with an aggregate market value of $741,249.6. The securities were acquired through stock appreciation rights on July 20, 2026, …

Viridian Therapeutics (VRDN) Stock Analysis: A Biotech Gem with Nearly 95% Upside Potential

Viridian Therapeutics (VRDN) is identified as a promising biotechnology company with significant growth potential, particularly in developing treatments for thyroid eye disease (TED) and Graves’ disease. Despite typical biotech financial metrics showing early-stage development, analysts forecast a nearly 95% upside potential, with an average …

Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31

Wells Fargo has reiterated its Buy rating for Viridian Therapeutics (VRDN.US) and maintained its target price at $31. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Viridis Mining and Minerals (ASX:VMM) Climbs Again—Is the Materials Stock Still on Investors' Radar?